CO5070621A1 - Metodo para incrementar el volumen oseo - Google Patents

Metodo para incrementar el volumen oseo

Info

Publication number
CO5070621A1
CO5070621A1 CO98051809A CO98051809A CO5070621A1 CO 5070621 A1 CO5070621 A1 CO 5070621A1 CO 98051809 A CO98051809 A CO 98051809A CO 98051809 A CO98051809 A CO 98051809A CO 5070621 A1 CO5070621 A1 CO 5070621A1
Authority
CO
Colombia
Prior art keywords
volume
oseo
increasing
subject
medicament
Prior art date
Application number
CO98051809A
Other languages
English (en)
Inventor
James Richard Hartke
Mark Walden Lundy
Mitchell Anthony Delong
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of CO5070621A1 publication Critical patent/CO5070621A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se relaciona con un agente que primariamente activa la proteína osteoblástica quinasa C y las vías intracelulares de calcio de un sujeto utilizado en la manufactura de un medicamento para aumentar el volumen óseo del sujeto.
CO98051809A 1997-09-09 1998-09-09 Metodo para incrementar el volumen oseo CO5070621A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5821897P 1997-09-09 1997-09-09

Publications (1)

Publication Number Publication Date
CO5070621A1 true CO5070621A1 (es) 2001-08-28

Family

ID=22015432

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98051809A CO5070621A1 (es) 1997-09-09 1998-09-09 Metodo para incrementar el volumen oseo

Country Status (17)

Country Link
EP (1) EP1035853A1 (es)
JP (1) JP2001515863A (es)
CN (1) CN1269720A (es)
AR (1) AR013478A1 (es)
AU (1) AU9130298A (es)
BR (1) BR9811775A (es)
CA (1) CA2303799A1 (es)
CO (1) CO5070621A1 (es)
HU (1) HUP0003584A3 (es)
ID (1) ID24759A (es)
IL (1) IL134759A0 (es)
NO (1) NO20001172L (es)
PE (1) PE118899A1 (es)
PL (1) PL339297A1 (es)
SK (1) SK3402000A3 (es)
WO (1) WO1999012550A1 (es)
ZA (1) ZA988229B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2232434T3 (es) 1999-03-05 2005-06-01 Duke University Analogos de prostaglandinas c-16 fp selectivas insaturadas.
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015767A1 (en) * 1992-02-05 1993-08-19 Merck & Co., Inc. Implant therapy for bone growth stimulation
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
BR9811775A (pt) 2000-08-29
IL134759A0 (en) 2001-04-30
ZA988229B (en) 1999-03-09
NO20001172D0 (no) 2000-03-07
AR013478A1 (es) 2000-12-27
PL339297A1 (en) 2000-12-04
JP2001515863A (ja) 2001-09-25
PE118899A1 (es) 2000-02-03
SK3402000A3 (en) 2000-12-11
AU9130298A (en) 1999-03-29
CN1269720A (zh) 2000-10-11
ID24759A (id) 2000-08-03
HUP0003584A3 (en) 2002-12-28
WO1999012550A1 (en) 1999-03-18
HUP0003584A2 (hu) 2001-02-28
EP1035853A1 (en) 2000-09-20
NO20001172L (no) 2000-05-08
CA2303799A1 (en) 1999-03-18

Similar Documents

Publication Publication Date Title
MX9306239A (es) Composicion farmaceutica que forma un gel de lecitina in vivo para la liberacion mantenida de un compuesto biologicamente activo y procedimiento para la preparacion de la misma.
ES2172670T3 (es) Pirrolpirimidinas y procedimientos para su preparacion.
ECSP105739A (es) Anticuerpos de neutralización contra gdf-8
DE69029257D1 (de) Anordnung zur bestrahlung von laserstrahlen
ES2183351T3 (es) Composicones que comprenden conjugados de proteina ob humana activa estable con una cadena fc de inmunoglobulinas y metodos.
SE8904036L (sv) Ledprotes, i synnerhet foer fotleder
CL2004001551A1 (es) Formula para infantes o de continuacion, que comprende una fuente de proteinas, lipidos, carbohidratos y un probiotico, donde al menos 40% de las proteinas son proteinas de suero dulce modificadas que comprenden una cantidad reducida de cgmp o no con
ES2173868T3 (es) Utilizacion de relaxina para la fabricacion de un medicamento destinado al tratamiento de enfermedades cardiovasculares.
AR013479A1 (es) Metodo para aumentar el volumen oseo utilizando agonistas de prostanoide f selectivos no naturales.
ES2083597T3 (es) Preparacion farmaceutica para el tratamiento del tiempo de coagulacion prolongado.
EE200200565A (et) Vaskulaarse kahjustava toimega kombinatsioonravi
DE69814394D1 (de) Verwendung von levobupivacain
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
ES2168766T3 (es) Preparacion farmaceutica que incluye el propeptido vwf.
CO5070621A1 (es) Metodo para incrementar el volumen oseo
DE68921210D1 (de) Weitenverstellbare schuhkonstruktion.
UY28533A1 (es) Aminoacidos con afinidad por la proteina alfa2delta
AR003001A1 (es) Composicion farmaceutica estimuladora de la osteogenesis.
ITMI20001257A0 (it) Composizione farmaceutica a base di prolina, glicina e lisina utile nella terapia per la cicatrizzazione delle ferite e delle lesioni tendin
RS50681B (sr) Kombinacija taksana i ciklin-zavisne kinaze
AR023464A1 (es) Usos novedosos de la proteina ox2 de mamifero y reactivos relacionados
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
BR0211323A (pt) Combinação de ingredientes ativos, uso de uma combinação de ingredientes ativos e método de terapia farmacológica de dependência de nicotina
PT1275383E (pt) Composicao farmaceutica de libertacao modificada que contem bupropion hc1 como substancia activa
ES2151489T3 (es) Procedimiento y composicion para el tratamiento de trastornos relacionados con herpes.